A new study found that spending on GLP-1 medications such as Ozempic, Wegovy and Zepbound surged to $5.8 billion in 2022 among U.S. adults without diabetes.
The research, published April 1 in the Annals of Internal Medicine, showed the number of non-diabetic adults using these drugs — which are also prescribed for weight loss — more than tripled from 2018 to 2022, rising from 0.1% to 0.4% of the U.S. population, or an estimated 854,000 people.
Despite the high cost, averaging $1,540 per prescription, patients paid around $35 out of pocket per fill, according to the study.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
